Glycoengineering approach to half-life extension of recombinant biotherapeutics

Bioconjugate Chemistry

Volumn 23, Issue 8, 2012, Pages 1524-1533

  Chen, Chen ^a   Constantinou, Antony ^a   Chester, Kerry A ^b   Vyas, Bijal ^a   Canis, Kevin ^a   Haslam, Stuart M ^a   Dell, Anne ^a   Epenetos, Agamemnon A ^a   Deonarain, Mahendra P ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; BIOCHEMISTRY; BLOOD; CHAINS; CHROMATOGRAPHIC ANALYSIS; ION CHROMATOGRAPHY; ION EXCHANGE; MASS SPECTROMETRY; MODULATION; MOLECULAR BIOLOGY; RECOMBINANT PROTEINS; SURFACE PLASMON RESONANCE;

ANTIBODY-FRAGMENT; BIODISTRIBUTIONS; BIOTHERAPEUTICS; HALF LIVES; LIFE EXTENSIONS; PEPTIDE PROTEINS; POLYSIALIC ACID; POLYSIALYLATION; PROTEIN ENGINEERING; SINGLE-CHAIN FV- ANTIBODY FRAGMENTS;

PHARMACOKINETICS;

CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCOSIDASE; MACROGOL; POLYSIALIC ACID; POLYSIALYLTRANSFERASE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRANSFERASE; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; BINDING KINETICS; BIOAVAILABILITY; BIOLOGICAL THERAPY; CARBOXY TERMINAL SEQUENCE; CELL STRAIN HEK293; CONFOCAL LASER MICROSCOPY; CONJUGATION; CONTROLLED STUDY; ENDOCYTOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GEL PERMEATION CHROMATOGRAPHY; GENETIC TRANSFECTION; GLYCOSYLATION; HUMAN; HUMAN CELL; HYDRODYNAMICS; IMMUNOFLUORESCENCE; INHIBITION KINETICS; ION EXCHANGE CHROMATOGRAPHY; KIDNEY CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULARLY TARGETED THERAPY; PLASMA HALF LIFE; POLYSIALYLATION; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; PROTEIN TARGETING; SURFACE PLASMON RESONANCE; WESTERN BLOTTING;

EID: 84865141761     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc200624a     Document Type: Article

References (36)

1. Holliger, P. and Hudson, P. J. (2005) Engineered antibody fragments and the rise of single domains Nat. Biotechnol. 23, 1126-36 (Pubitemid 41486394)
2. Gebauer, M. and Skerra, A. (2009) Engineered protein scaffolds as next-generation antibody therapeutics Curr. Opin. Chem. Biol. 13, 245-55
3. Fukumura, D. and Jain, R. K. (2007) Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize J. Cell Biochem. 101, 937-49 (Pubitemid 47040874)
4. Graff, C. P. and Wittrup, K. D. (2003) Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention Cancer Res. 63, 1288-96 (Pubitemid 36348707)
5. Dougan, M. and Dranoff, G. (2009) The immune response to tumors. In Current Protocols in Immunology, Chapter 20, Unit 20.11, John Wiley & Sons, New Jersey.
6. Jevsevar, S., Kunstelj, M., and Porekar, V. G. (2010) PEGylation of therapeutic proteins Biotechnol. J. 5, 113-28
7. Chen, C., Constantinou, A., and Deonarain, M. (2011) Modulating antibody pharmacokinetics using hydrophilic polymers Expert Opin. Drug Delivery 8, 221-36
8. Deen, W. M., Bohrer, M. P., and Brenner, B. M. (1979) Macromolecule transport across glomerular capillaries: application of pore theory Kidney Int. 16, 353-65 (Pubitemid 10208497)
9. Gaberc-Porekar, V., Zore, I., Podobnik, B., and Menart, V. (2008) Obstacles and pitfalls in the PEGylation of therapeutic proteins Curr. Opin. Drug Discovery Devel. 11, 242-50 (Pubitemid 351281064)
10. Armstrong, J. K., Hempel, G., Koling, S., Chan, L. S., Fisher, T., Meiselman, H. J., and Garratty, G. (2007) Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients Cancer 110, 103-11 (Pubitemid 46986423)
11. Muhlenhoff, M., Eckhardt, M., and Gerardy-Schahn, R. (1998) Polysialic acid: three-dimensional structure, biosynthesis and function Curr. Opin. Struct. Biol. 8, 558-64 (Pubitemid 28486380)
12. Constantinou, A., Chen, C., and Deonarain, M. P. (2012) Polysialic acid and polysialylation to modulate antibody pharmacokinetics. In in Pharmacokinetic modulation of therapeutic proteins (Kontermann, R, Ed) Wiley, London (in press).
13. Constantinou, A., Epenetos, A. A., Hreczuk-Hirst, D., Jain, S., and Deonarain, M. P. (2008) Modulation of antibody pharmacokinetics by chemical polysialylation Bioconjugate Chem 19, 643-50 (Pubitemid 351431395)
14. Constantinou, A., Epenetos, A. A., Hreczuk-Hirst, D., Jain, S., Wright, M., Chester, K. A., and Deonarain, M. P. (2009) Site-specific polysialylation of an antitumor single-chain Fv fragment Bioconjugate Chem. 20, 924-31
15. Fernandes, A. I. and Gregoriadis, G. (1997) Polysialylated asparaginase: preparation, activity and pharmacokinetics Biochim. Biophys. Acta 1341, 26-34 (Pubitemid 27357031)
16. Mühlenhoff, M., Oltmann-Norden, I., Weinhold, B., Hildebrandt, H., and Gerardy-Schahn, R. (2009) Brain development needs sugar: the role of polysialic acid in controlling NCAM functions Biol Chem. 390, 567-74
17. Umaña, P., Jean-Mairet, J., Moudry, R., Amstutz, H., and Bailey, J. E. (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity Nat. Biotechnol. 17, 176-80 (Pubitemid 29072543)
18. Elliott, S., Lorenzini, T., Asher, S., Aoki, K., Brankow, D., Buck, L., Busse, L., Chang, D., Fuller, J., Grant, J., Hernday, N., Hokum, M., Hu, S., Knudten, A., Levin, N., Komorowski, R., Martin, F., Navarro, R., Osslund, T., Rogers, G., Roger,s, N., Trail, G., and Egrie, J. (2003) Enhancement of therapeutic protein in vivo activities through glycoengineering Nat. Biotechnol. 21, 414-21 (Pubitemid 36397662)
19. Sainz-Pastor, N., Tolner, B., Huhalov, A., Kogelberg, H., Lee, Y. C., Zhu, D., Begent, R. H., and Chester, K. A. (2006) Deglycosylation to obtain stable and homogeneous Pichia pastoris-expressed N-A1 domains of carcinoembryonic antigen Int. J. Biol. Macromol. 39, 141-50 (Pubitemid 44066550)
20. Beecken, W. D., Engl, T., Ogbomo, H., Relja, B., Cinatl, J., Bereiter-Hahn, J., Oppermann, E., Jonas, D., and Blaheta, R. A. (2005) Valproic acid modulates NCAM polysialylation and polysialyltransferase mRNA expression in human tumor cells Int. Immunopharmacol. 5, 757-69 (Pubitemid 40248330)
21. Nelson, R. W., Bates, P. A., and Rutishauser, U. (1995) Protein determinants for specific polysialylation of the neural cell adhesion molecule J. Biol. Chem. 270, 17171-9
22. Colley, K. J. (2010) Structural basis for the polysialylation of the neural cell adhesion molecule Adv. Exp. Med. Biol. 663, 111-26
23. Begent, R. H., Verhaar, M. J., Chester, K. A., Casey, J. L., Green, A. J., Napier, M. P., Hope-Stone, L. D., Cushen, N., Keep, P. A., Johnson, C. J., Hawkins, R. E., Hilson, A. J., and Robson, L. (1996) Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library Nat. Med. 2, 979-84 (Pubitemid 26306835)
24. Foley, D. A., Swartzentruber, K. G., and Colley, K. J. (2009) Identification of sequences in the polysialyltransferases ST8Sia II and ST8Sia IV that are required for the protein-specific polysialylation of the neural cell adhesion molecule, NCAM J. Biol. Chem. 284, 15505-16
25. Perera, A. D., Lagenaur, C. F., and Plant, T. M. (1993) Postnatal expression of polysialic acid-neural cell adhesion molecule in the hypothalamus of the male rhesus monkey (Macaca mulatta) Endocrinology 133, 2729-35 (Pubitemid 24000727)
26. Galuska, S. P., Geyer, R., Mühlenhoff, M., and Geyer, H (2007) Characterization of oligo- and polysialic acids by MALDI-TOF-MS Anal. Chem. 79, 7161-9 (Pubitemid 47438698)
27. Schier, R., Bye, J., Apell, G., McCall, A., Adams, G. P., Malmqvist, M., Weiner, L. M., and Marks, J. D. (1996) Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection J. Mol. Biol. 255, 28-43 (Pubitemid 26104182)
28. Müller, D., Karle, A., Meissburger, B., Höfig, I., Stork, R., and Kontermann, R. E. (2007) Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin J. Biol. Chem. 288, 12650-60 (Pubitemid 47100581)
29. Deen, W. M., Lazzara, M. J., and Myers, B. D. (2001) Structural determinants of glomerular permeability Am. J. Physiol. Renal Physiol. 281, 579-96
30. Kubetzko, S., Sarkar, C. A., and Plückthun, A. (2005) Protein PEGylation decreases observed target association rates via a dual blocking mechanism Mol. Pharmacol. 68, 1439-54 (Pubitemid 41540000)
31. Kuimova, M. K., Bhatti, M., Deonarain, M., Yahioglu, G., Levitt, J. A., Stamati, I., Suhling, K., and Phillips, D. (2007) Fluorescence characterisation of multiply-loaded anti-HER2 single chain Fv-photosensitizer conjugates suitable for photodynamic therapy Photochem. Photobiol. Sci. 6, 933-9 (Pubitemid 47313199)
32. Scheler, S., Kitzan, M., and Fahr, A. (2011) Cellular uptake and degradation behaviour of biodegradable poly(ethylene glycol-graft-methyl methacrylate) nanoparticles crosslinked with dimethacryloyl hydroxylamine Int. J. Pharm. 403, 207-18
33. Anthony, R. M. and Ravetch, J. V. (2010) A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs J. Clin. Immunol. 30 (SUPPL. 1) S9-14
34. Schlapschy, M., Theobald, I., Mack, H., Schottelius, M., Wester, H. J., and Skerra, A. (2007) Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life Protein Eng. Des. Sel. 20, 273-84 (Pubitemid 47227182)
35. Schellenberger, V., Wang, C. W., Geething, N. C., Spink, B. J., Campbell, A., To, W., Scholle, M. D., Yin, Y., Yao, Y., Bogin, O., Cleland, J. L., Silverman, J., and Stemmer, W. P. (2009) A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner Nat. Biotechnol. 27, 1186-90
36. Nelson, A. L. and Reichert, J. M. (2009) Development trends for therapeutic antibody fragments Nat. Biotechnol. 27, 331-7